Life sciences research provides scientific and economic benefits to society; however, this knowledge, information, products, or technologies could also pose a significant threat if misapplied. Such research is referred to Dual Use Research of Concern (DURC).
The National Science Advisory Board for Biosecurity (NASABB) has developed a policy which identifies seven categories of experiments involving tier one select agents in any amount as DURC. The “United States Government Policy for Institutional Oversight of Life Sciences Dual Use Research of Concern,” addresses institutional oversight of DURC that must be implemented by September 24, 2015. The purpose of this policy is to strengthen ongoing institutional review and oversight of certain life sciences research with high-consequence pathogens and toxins in order to identify potential DURC and mitigate risks where appropriate.
A subset of life sciences research known as “gain-of-function” studies focuses on understanding disease pathways by increasing the ability of infectious agents to cause disease by enhancing its pathogenicity or by increasing its transmissibility. The U.S. Government has instituted a pause on funding for any new research and encourages those currently conducting this type of work – whether federally funded or not – to voluntarily pause their research while risks and benefits are being reassessed.
The funding pause will affect gain-of-function experiments involving influenza, SARS, and MERS viruses that would have enhanced pathogenicity and/or transmissibility in mammals via the respiratory route. It will not apply to the characterization or testing of naturally occurring influenza, MERS, and SARS viruses unless there is a reasonable expectation that these tests would increase transmissibility or pathogenicity.
The deliberative process will involve two distinct but complementary entities: the National Science Advisory Board for Biosecurity (NSABB) and the National Research Council (NRC) of the National Academies and is outlined in the document entitled; “U.S. Government Gain-of-Function Deliberative Process and Research Funding Pause on Selected Gain-of-Function Research Involving Influenza, MERS, and SARS Viruses” and is expected to be completed in one year.